Clovis Oncology Company Profile (NASDAQ:CLVS)

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (?)
Ratings Breakdown: 6 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $32.11 (121.61% upside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Stifel NicolausReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Piper Jaffray Cos.Reiterated RatingHold$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016WallachBeth CapitalLower Price TargetHold$30.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016MizuhoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$42.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Leerink SwannBoost Price TargetOutperform$104.00 -> $110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$23.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Citigroup Inc.Boost Price TargetNeutral$60.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Clovis Oncology (NASDAQ:CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($2.44)($3.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.99)($2.10)$1.17 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.82)($1.86)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414($1.30)($1.62)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($1.07)($1.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.96)($1.03)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline
07/26/16 03:09 PMClovis Oncology (CLVS) Shares are Down -1.39% - Trade Calls
07/26/16 03:05 PMClovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8 - [Business Wire] - Clovis Oncology, Inc. will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
07/22/16 10:46 AMEarnings Focus and Crowd Sourced Sentiment Review for Clovis Oncology, Inc. (NASDAQ:CLVS) - TGP
07/21/16 03:22 PMClovis Oncology Inc Increases Again; Strong Momentum for Buyers - Press Telegraph
07/20/16 10:37 PMClovis Oncology Inc Stock Technicals Hit Weakness - CML News
07/20/16 10:37 PMClovis Oncology, Inc. (NASDAQ:CLVS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 03:29 PMTrading Performance and Target Watch for Clovis Oncology, Inc. (NASDAQ:CLVS) - Press Telegraph
07/18/16 03:29 PMWere Analysts Bearish Clovis Oncology Inc (NASDAQ:CLVS) This Week? - Consumer Eagle
07/16/16 06:12 AMShares Experiencing a Downtrend: Clovis Oncology, Inc. (NASDAQ:CLVS) - TGP
07/15/16 02:19 PMClovis Oncology Incorporated (NASDAQ:CLVS) Shorted Shares Increased 0.2% After Market Selling - Press Telegraph
07/15/16 02:19 PMClovis Oncology Inc. (CLVS) Drops 6.8% on July 13 - Equities.com
07/13/16 08:39 PMShares Losing Ground for the Month; Investor Alert on Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
07/13/16 11:21 AMAnalyst Target and Average Rating Watch: Clovis Oncology, Inc. (NASDAQ:CLVS) - Press Telegraph
07/12/16 08:42 PMClovis Oncology, Inc. (NASDAQ:CLVS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 03:15 PMToday's Watch List: ServiceNow, Inc. (NYSE:NOW), Clovis Oncology, Inc. (NASDAQ:CLVS), Sealed Air Corporation ... - KC Register
07/11/16 08:03 AMClovis Oncology Incorporated (NASDAQ:CLVS) Sellers Increased By 0.2% Their Shorts - Engelwood Daily
07/09/16 05:46 AMShares Finishing Down for the Week Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
07/07/16 03:17 PMHeightened Volatility Check on: Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
07/07/16 10:58 AMClovis Oncology Inc. (CLVS) Jumps 5.48% on July 06 - Equities.com
07/06/16 03:21 PMClovis Oncology Inc. (CLVS) Jumps 7.07% on July 04 - Equities.com
07/05/16 03:15 PMNew Report Available: Clovis Oncology, Inc. (CLVS) - Financial and Strategic SWOT Analysis Review
07/05/16 08:00 AMClovis Oncology Incorporated (NASDAQ:CLVS) Shorted Shares Increased 0.2% After Market Selling - Engelwood Daily
07/03/16 07:55 AMClovis Oncology Inc. (CLVS) is Trading Lower on Unusual Volume for June 30 - Equities.com
07/03/16 07:55 AMClovis Oncology Inc. (CLVS) Jumps 7.07% on July 01 - Equities.com
07/01/16 08:24 PMTracking Stock Volatility for: Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
07/01/16 02:40 PMAn Overnight Double! Could These Drugmakers Be Next? -
07/01/16 11:07 AMProminent Runners: Chromadex (NASDAQ:CDXC), Clovis Oncology (NASDAQ:CLVS), Atlas Resource Partners ... - iStreetWire
07/01/16 11:07 AMWhy Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today's Best Stocks - Investorplace.com
06/30/16 10:55 AMClovis Oncology Inc. (CLVS) Is Surging In Early Trade
06/30/16 10:55 AMClovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session
06/30/16 10:55 AMClovis Oncology Incorporated (NASDAQ:CLVS) Shorted Shares Increased 0.2% After Market Selling
06/29/16 04:46 PMWhy Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips It was a good day for the stock market, but TSRO, CLVS and TWLO managed to stand out from the pack. The post Why Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks appeared first on InvestorPlace.
06/29/16 03:14 PMClovis Higher In Sympathy With Tesaro
06/29/16 02:00 PMWhat's Causing Clovis Oncology Shares to Skyrocket Today? - A late-stage trial win for Tesaro may increase the chances that Clovis Oncology's similar drug will pan out, too.
06/29/16 11:20 AMWatching Stock Volatility for: Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
06/29/16 11:20 AMClovis Oncology Inc. (CLVS) Jumps 6.78% on June 28 - Equities.com
06/29/16 10:49 AMHere’s Why These Five Stocks Are On the Move on Wednesday -
06/29/16 10:06 AMThese 15 Biotech Companies Could Be Takeover Targets -
06/29/16 08:45 AMClovis Oncology gets a bump from TESARO's success; shares up 17% premarket -
06/28/16 08:09 AMClovis Oncology, Inc. (CLVS) Trades at 52-Week Low - Finance Daily
06/28/16 08:09 AMClovis Oncology, Inc. (NASDAQ:CLVS) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 08:04 AM5 Reasons to Hate Biotech Stocks -
06/20/16 02:21 PMSexy vs. Boring: Who’s Winning? - [ETFguide] - Higher investment risk leads to higher investment returns, right? It’s a Wall Street axiom that we’ve heard so many times it’s become ingrained in us. But conventional wisdom and reality have the peculiar ...
06/19/16 03:05 PMThis Weeks Broker Views For Clovis Oncology, Inc. (NASDAQ:CLVS) - Fiscal Standard
06/12/16 11:02 AMClovis Oncology files $200M shelf registration
06/11/16 03:22 PMEarnings Report: Clovis Oncology, Inc. (NASDAQ:CLVS), InvenSense, Inc. (NYSE:INVN) - Beacon Chronicle
06/10/16 07:32 AMCLOVIS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 06:37 AMBRIEF-Clovis Oncology Inc files for mixed shelf of up to $200 mln - * Clovis Oncology Inc files for mixed shelf of up to $200 million Source text: http://1.usa.gov/1XdI04i Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
06/09/16 09:19 AMYesterday's Consideration Movers: Neovasc Inc. (NASDAQ:NVCN) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates
06/09/16 09:19 AMClovis Oncology Inc. (CLVS) Drops 5.48% on June 07 - Equities.com

Social

About Clovis Oncology

Clovis Oncology logoClovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLVS
  • CUSIP: 18946410
Key Metrics:
  • Previous Close: $14.49
  • 50 Day Moving Average: $14.07
  • 200 Day Moving Average: $16.89
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $556.20M
  • Beta: 2.15
  • Current Year EPS Consensus Estimate: $-8.00 EPS
  • Next Year EPS Consensus Estimate: $-4.85 EPS
Additional Links:
Clovis Oncology (NASDAQ:CLVS) Chart for Thursday, July, 28, 2016